SIRT1 and SIRT3 are key melatonin targets; in rats, melatonin efficiently alleviates glucose metabolism disorders by decreasing mitochondrial dysfunction through activating SIRT1 and SIRT3 (Chen et al., 2019; Zhang et al., 2017). Here, SIRT3 is linked to glucose metabolism disease.